Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 10/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7326117 | 0.91 | MAPT (0.31) | ITGB3ITGA2BF2F10 | |
| SCHEMBL7331017 | 0.91 | KDM4E (0.31) | MDM2ITGB3ITGA2BF2F10 | |
| SCHEMBL7330344 | 0.91 | MDM2 (0.36) | MDM2ITGB3ITGA2BF2F10 | |
| SCHEMBL7331638 | 0.87 | MDM2 (0.36) | MDM2ITGB3ITGA2BF2F10 | |
| SCHEMBL7332372 | 0.86 | HDAC1 (0.39) | MDM2ITGB3ITGA2BF2F10 | |
| SCHEMBL7318601 | 0.85 | TPSAB1 (0.36) | MDM2ITGB3ITGA2BF2F10 | |
| SCHEMBL7354809 | 0.84 | ITGB3 (0.34) | MDM2ITGB3ITGA2BF2F10 | |
| SCHEMBL7324864 | 0.82 | KDM4E (0.32) | MDM2TP53 | |
| SCHEMBL7323160 | 0.82 | MDM2 (0.54) | MDM2TP53 | |
| SCHEMBL7327913 | 0.82 | MEN1 (0.38) | ITGB3ITGA2BF2F10GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5663166-A | ANTICOAGULANTS OF 1,4-BENZODIAZEPINE-2,5-DIONE AND 2-BENZOAZEPINE-1,4-DIONE DERIVATIVES; PREVENTS FIBRINOGEN BINDING NECESSARY FOR PLATELET AGGREGATION; SIDE EFFECT REDUCTION, E.G. EXCESSIVE BLEEDING | GENENTECH, INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5565449-A | PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0610334-B1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII B III A RECEPTOR | GENENTECH INC (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5403836-A | Anticoagulants | GENENTECH, INC. (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0610334-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII b?III a? RECEPTOR. | GENENTECH INC (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5250679-A | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor | GENENTECH, INC. (US) | 1993-10-05 | — | — | US | disclosed |
| WO-1993008174-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPIIbIIIa RECEPTOR | GENENTECH, INC. (US) | 1993-04-29 | — | — | WO | disclosed |